A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Study acronym: LIMIT
StatusActive, Not Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 31, 2026 → Nov 13, 2026
See other at-risk trials from Ravi Amaravadi, MD

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Nov 13, 2026 to Jul 30, 2026
    • Eligibility criteria expanded, about 28 words
  2. Primary completion pushed from Jul 31, 2026 to Nov 13, 2026v10
  3. Enrollment reduced: 94 → 41 participantsv9 Show 4 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Primary completion moved earlier from Jan 6, 2027 to Jul 31, 2026
    • Study completion pushed from Jan 6, 2027 to May 12, 2027
    • Site details revised
  4. Primary and study completion dates: Oct 30, 2025 to Jan 6, 2027v8
  5. Site contact updatedv7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Primary and study completion dates: Oct 30, 2023 to Oct 30, 2025v5
  3. 2 versions Re-verified since Sep 15, 2021, no change to tracked fieldsv3-v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jul 30, 2023 to Oct 30, 2023
    • Start date changed from estimate of Jul 30, 2020 to Oct 21, 2020
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ravi Amaravadi, MD
1 trial monitored
See 1 trial at risk
Melanoma
1,093 trials monitored
See 62 trials at risk
This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Trial Details
NCT Number NCT04464759
Lead Sponsor Ravi Amaravadi, MD
Collaborators: Bristol-Myers Squibb
Conditions
(from sponsor)		 Melanoma
Related terms Melanoma
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov